Amgen gets FDA approval for osteoporosis drug Evenity

You are here: Home > Biotech > Current Article

Amgen gets FDA approval for osteoporosis drug Evenity

By Staff Report / Tuesday, April 9th, 2019 / Comments Off on Amgen gets FDA approval for osteoporosis drug Evenity

An osteoporosis treatment from Thousand Oaks biotech giant Amgen received FDA approval to treat postmenopausal women, who are at a high risk for bone fractures. The approval follows data from two Phase 3 studies of the drug, called Evenity, that showed significant reductions in spine fractures and increases in bone mineral density compared to a…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.